echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > The first batch of approved drugs will be donated to the front line of "anti epidemic"

    The first batch of approved drugs will be donated to the front line of "anti epidemic"

    • Last Update: 2020-02-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On February 16, 2020, Zhejiang Haizheng Pharmaceutical Co., Ltd (hereinafter referred to as Haizheng pharmaceutical) announced that it had received the approval document from the drug evaluation center of the State Drug Administration (hereinafter referred to as CDE) "on the conditional approval for the listing of faveravir tablets (also referred to as fapiravir tablets)", and the product was approved for listing for clinical treatment and research from now on Novel coronavirus tablets were first donated to the epidemic front line by the Zhejiang provincial government and the Taizhou municipal government together with the Hai Zheng pharmaceutical company The novel coronavirus was successfully tackled by researchers in China since February 15th, according to the press conference information of the joint defense and joint control mechanism of the State Council A total of 70000 drugs were screened nationwide, and 5000 potentially effective products were selected 100 of them were selected and tested in vitro, and finally focused on three drugs, such as faveravir In the clinical trials of more than 70 cases, the efficacy and side effects of familavir tablets were obvious On the third to fourth days after treatment, the negative rate of viral nucleic acid in the treatment group was significantly higher than that in the control group As early as the first time of anti epidemic, Haizheng pharmaceutical industry has urgently supported medical institutions to carry out clinical trials A novel coronavirus pneumonia was launched in January 30th by the national infectious disease clinical medical research center and the third people's Hospital of Shenzhen (Second Affiliated Hospital of Southern University of science and Technology) On February 14, the third people's Hospital of Shenzhen released "clinical trials show that the antiviral effect of fapiravir is better than that of klitschke" on its official website The article shows that there is no obvious adverse reaction in the treatment group, the side effect is significantly lower than that in the treatment group, the patients' compliance is good, and the antiviral effect is better than that in the treatment group It is suggested that the scale of clinical application of faveravir tablets can be expanded Public information shows that faveravir tablet is a new mechanism drug, belonging to RNA dependent RNA polymerase (RdRp) inhibitors of broad-spectrum anti influenza virus drugs The drug was launched in Japan in 2014, used to treat new and recurrent influenza, and became the national strategic reserve drug of Japan The approved indications of Haizheng faveravir tablets are also influenza related indications In addition, novel coronavirus is also a kind of RNA virus, which has been shown to have good inhibitory effects on virulent RNA viruses in filamentous, bunyavirus and grycovirivirus in vitro and in vivo As early as 2016, Haizheng pharmaceutical signed an exclusive license agreement for compound patent with the original manufacturer, Fushan Chemical Industry Co., Ltd of Japan, and then signed a technical cooperation agreement with the Institute of toxicants and drugs (hereinafter referred to as the Academy of Military Medical Sciences) of the Military Medical Research Institute of the people's Liberation Army But then, due to the problems of enterprise funds and personnel, the project was pushed forward very slowly In 2019, the Company re combed the product pipeline, vigorously carried out R & D reform, cut off a number of repetitive and inefficient projects, focused on core projects, listed the potential significant projects such as faveravir tablets as key projects, accelerated the promotion of pharmaceutical and clinical research, and completed the fasting be test in 2019, showing that Haizheng faveravir tablets are equivalent to the original research, with good safety Relevant pharmaceutical research shows that the quality of Haizheng pharmaceutical faveravir tablets is consistent with the original research With the official approval of Haizheng faveravir tablets, Haizheng pharmaceutical will also carry out the registration clinical trials for the treatment of indications of new coronavirus pneumonia, which has been officially approved by the state The clinical trial is a double-blind, randomized, controlled study, and is expected to end in three months Recently, the central government pointed out that it is necessary to improve the system and mechanism of major epidemic prevention and control As a comprehensive large-scale state-owned pharmaceutical enterprise with R & D as its core competitiveness, Haizheng pharmaceutical industry will increase its investment in projects of great public health significance, contributing to the construction of national public health emergency system.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.